Justin is a partner specialising in venture and growth capital work for early stage and growing technology companies and the investors who support them.

He advises companies, investors and founders on venture and growth capital transactions at all stages from pre-seed through seed, Series A and on to larger institutional investment rounds. He also advises on M&A/exit deals and corporate matters generally.

His practice covers all aspects of the technology sector, but he has a focus on deals in the life sciences sector, and a particular expertise in advising in relation to commercialisation deals involving technologies developed at the UK's leading universities and research institutions.

Justin co-leads OC Ventures, Osborne Clarke's resource centre for the ventures ecosystem.

Helping you succeed in tomorrow's world

The UK is a really exciting place to be involved in science and innovation. I use my experience and knowledge to help the successful commercialisation of the best ideas. This can mean offering guidance and mentoring to founders of new companies or delivering complex funding or exit transactions – all of which is rewarding and always interesting.

Clients praise Justin Starling's ability to get to the issue quickly and always focus on the commercial importance rather than getting bogged down in legal arguments. He is well versed in the representation of investors and investees in the venture capital space, and is particularly active in the technology sector.

Venture Capital UK, Chambers and Partners
Advent Life Sciences/Proximie Series C

Advised Advent Life Sciences on its lead investment in global health technology platform Proximie's $80m Series C funding round.

Optellum/Series A

Advised Oxford based AI lung cancer diagnosis innovator Optellum on $14m Series A funding. round.

CloudFactory/Acquisition of Hasty GmbH

Advised CloudFactory, a global leader in human-in-the-loop artificial intelligence (AI), on its acquisition of Hasty, a data-centric machine learning (ML) platform that allows companies to build and deploy vision AI applications faster and more reliably.

Albion VC/Toqio Series A

Advised Albion VC on the £17m Series A funding of fintech SaaS provider Toqio.

Mestec/Acquisition by Eyelit Inc.

Advised on the sale of Mestec, a cloud based SaaS provider in complex manufacturing automation, to Eyelit Inc.

Epitopea/Series A

Advised a syndicate of international investors including Cambridge Innovation Capital, Advent Life Sciences, CTI Life Sciences and FSTQ on their $14m dual UK/Canadian funding of Epitopea to advance cancer immunotherapeutics.

Argonaut Therapeutics Ltd

We advised Argonaut Therapeutics Ltd, a spin-out from the University of Oxford, on its merger with Celleron Therapeutics Ltd., another Oxford spin-out, to form IngenOx Therapeutics.

UCL Technology Fund/Apollo Healthcare

Advised the UCL Technology Fund on its investment in Apollo Therapeutics as part of a $145 million financing led by Patient Square Capital, with participation from additional investors including Rock Springs Capital and Reimagined Ventures.


News and deals